2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 812

Monocytes/Neurotrophins/Myofibroblasts As a Novel Axis in Systemic Sclerosis
Abstract Number: 2280

Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout
Abstract Number: 2281

Monosodium Urate Monohydrate (MSU) Crystals Induces Cartilage Degeneration By Accelerating Hypertrophy and Mineralization.
Abstract Number: 1614

Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis
Abstract Number: 1170

Month of Birth Affects the Risk of Rheumatic Diseases: A Nationwide Case-Control Study
Abstract Number: 1026

Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Abstract Number: 1351

Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Abstract Number: 1192

Mortality and Survival of Patients Diagnosed with GCA in Bergen (Western Norway) 1972-2012
Abstract Number: 1250

Mortality in Indigenous Populations of Canada, the United States, Australia, and New Zealand with Rheumatic Disease: A Systematic Review
Abstract Number: 3065

Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies
Abstract Number: 523

Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Abstract Number: 1193

Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis
Abstract Number: 3169

Mortality Trends in Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Abstract Number: 1931

MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life
Abstract Number: 1308

MRI of Bilateral Hands Prevents Clinicians from Failing to Detect Joint Damage of Patients with Rheumatoid Arthritis Compared to Scanning Unilateral Hand

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].